Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Talis Biomedical Corporation (TLIS : NSDQ)
 
 • Company Description   
Talis Biomedical Corporation engaged in developing and commercializing products for infectious diseases at the point-of-care. The company involved in developing the Talis One platform, a compact, sample-to-answer, cloud-enabled, molecular diagnostic platform. Talis Biomedical Corporation is based in MENLO PARK, Calif.

Number of Employees: 262

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.02 Daily Weekly Monthly
20 Day Moving Average: 183,914 shares
Shares Outstanding: 26.62 (millions)
Market Capitalization: $27.15 (millions)
Beta: 0.93
52 Week High: $12.88
52 Week Low: $0.96
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -7.27% 4.44%
12 Week -50.24% -45.30%
Year To Date -74.56% -68.92%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
230 CONSTITUTION DRIVE
-
MENLO PARK,CA 94025
USA
ph: 650-433-3000
fax: -
ir@talisbio.com https://talisbio.com
 
 • General Corporate Information   
Officers
Robert J. Kelley - Chief Executive Officer
J. Roger Moody - Chief Financial Officer
Felix Baker - Director
Raymond Cheong - Director
Melissa Gilliam - Director

Peer Information
Talis Biomedical Corporation (CORR.)
Talis Biomedical Corporation (RSPI)
Talis Biomedical Corporation (CGXP)
Talis Biomedical Corporation (BGEN)
Talis Biomedical Corporation (GTBP)
Talis Biomedical Corporation (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 87424L108
SIC: 3826
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/09/22
Share - Related Items
Shares Outstanding: 26.62
Most Recent Split Date: (:1)
Beta: 0.93
Market Capitalization: $27.15 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.82 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-3.56 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: 38.52% Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/09/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.13
Price/Cash Flow: -
Price / Sales: 6.20
EPS Growth
vs. Year Ago Period: 72.89%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: -54.47%
vs. Previous Quarter: 271.45%
ROE
03/31/22 - -66.55
12/31/21 - -67.21
09/30/21 - -103.75
ROA
03/31/22 - -55.84
12/31/21 - -56.83
09/30/21 - -64.65
Current Ratio
03/31/22 - 13.15
12/31/21 - 12.36
09/30/21 - 8.86
Quick Ratio
03/31/22 - 12.92
12/31/21 - 12.36
09/30/21 - 8.86
Operating Margin
03/31/22 - -3,757.88
12/31/21 - -2,343.90
09/30/21 - -2,742.84
Net Margin
03/31/22 - -3,757.88
12/31/21 - -2,343.90
09/30/21 - -2,742.84
Pre-Tax Margin
03/31/22 - -3,757.88
12/31/21 - -2,343.90
09/30/21 - -2,742.84
Book Value
03/31/22 - 7.62
12/31/21 - 8.90
09/30/21 - 10.07
Inventory Turnover
03/31/22 - 4.03
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©